Highlights

• Pro Medicus jumped 2.74% to $177.43 on 4 September 2026

• Underlying Revenue grew 28% in constant-currency terms in FY2026

• EBIT Margin expanded to 74.9% in FY2026

• FY2026 results presented on 18 August 2026 alongside operational updates

Pro Medicus Ltd (ASX:PME) was among the strongest performers in the healthcare sector on 4 September 2026, rising 2.74% to $177.43. The Melbourne-based radiology software company continues to attract strong investor interest on the back of exceptional FY2026 results that demonstrated both rapid revenue growth and one of the highest EBIT margins of any ASX-listed technology business.

About the Company

Pro Medicus is an Australian healthcare technology company that develops and sells radiology software and services to hospitals, imaging centres and health networks globally. Its flagship Visage Imaging platform provides advanced medical imaging solutions covering workflow, reading, and AI-assisted diagnostics. Pro Medicus has successfully expanded into the United States, where it holds contracts with major academic medical centres and hospital systems. The company is widely regarded as one of Australia's highest-quality software businesses.

Key Developments

Pro Medicus reported FY2026 results showing underlying revenue growth of 28% in constant-currency terms. EBIT margin expanded to 74.9%. The company's FY2026 financial report and Appendix 4E were released through its investor financial-results centre. The results were presented on 18 August 2026 alongside operational and financial updates.

Key Catalysts to Watch

• New contract wins with US health systems or international hospital networks

• Expansion of AI and advanced analytics features within the Visage platform

• Progress into European and Asian markets

• Any FY2027 guidance or revenue contract pipeline updates

Risks

• Elevated valuation multiple leaves the stock vulnerable to Earnings misses

• Competition from global imaging software providers including Sectra and Philips

• Concentration risk with a relatively small number of large US contracts

• Currency exposure given substantial USD-denominated revenue

Conclusion

Pro Medicus is one of the rare ASX-listed companies combining rapid revenue growth with extraordinary profitability, and FY2026's 74.9% EBIT margin underscores just how capital-light and scalable its software model is. The 2.74% gain on 4 September reflects the market's continued enthusiasm for the PME growth story. New contract announcements and international expansion remain the key catalysts to watch. At elevated multiples, execution remains critical, but the quality of the Business is hard to argue against.